Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors of surgical site infection in total knee arthroplasty: Impact of an infection prevention and control intervention in a tertiary hospital in Barcelona, Spain.
Zules-Oña R, Otero-Romero S, Rodrigo-Pendás JA, Minguell-Monyart J, Amat-Mateu C, Lung M, Martínez-Gómez X, Quintana-Alonso C, Limón E, Parés-Badell O. Zules-Oña R, et al. Among authors: martinez gomez x. Am J Infect Control. 2026 Jan 3:S0196-6553(25)00777-1. doi: 10.1016/j.ajic.2025.12.016. Online ahead of print. Am J Infect Control. 2026. PMID: 41490525 Free article.
Safety monitoring of GSK's quadrivalent seasonal influenza vaccine in European countries during the 2023/24 flu season: A multicenter, non-interventional study.
Salamanca de la Cueva I, Brotons C, Maier P, Pirçon JY, Gupta V, Eckermann T, Nikic V, Martinez Gomez X, Alsdurf H. Salamanca de la Cueva I, et al. Among authors: martinez gomez x. Hum Vaccin Immunother. 2025 Dec;21(1):2569735. doi: 10.1080/21645515.2025.2569735. Epub 2025 Oct 20. Hum Vaccin Immunother. 2025. PMID: 41114673 Free PMC article.
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients.
Mayorga Ayala L, Herrera-deGuise C, Esperalba J, Martinez-Gomez X, Céspedes Martinez E, Serra Ruiz X, Robles V, Lastiri E, Perez Z, Oller E, Fernandez-Naval C, Martinez-Gallo M, Casellas F, Borruel N. Mayorga Ayala L, et al. Among authors: martinez gomez x. Cells. 2025 Jul 26;14(15):1156. doi: 10.3390/cells14151156. Cells. 2025. PMID: 40801589 Free PMC article.
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, Kiertiburanakul S, Kim AHJ, Longbrake EE, Molina JM, Paredes R, Tucker D, Uriel A, Weinmann-Menke J, Aksyuk AA, Clegg LE, Currie A, Yang H, Flyrin K, Gibbs M, Shroff M, Perez JL, Chang LJ, Cohen TS; SUPERNOVA study group. Haidar G, et al. Lancet Infect Dis. 2025 Jul;25(7):813-826. doi: 10.1016/S1473-3099(24)00804-1. Epub 2025 Feb 24. Lancet Infect Dis. 2025. PMID: 40015292 Clinical Trial.
Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
Carvajal R, Guananga-Álvarez D, Tur C, Esperalba J, Rodríguez-Barranco M, Rando-Segura A, Borras-Bermejo B, Cobo-Calvo A, Carbonell-Mirabent P, Zules-Oña R, Rodrigo-Pendas JA, Martínez-Gómez X, Montalban X, Tintore M, Otero-Romero S. Carvajal R, et al. Among authors: martinez gomez x. Neurology. 2025 Feb 11;104(3):e210281. doi: 10.1212/WNL.0000000000210281. Epub 2025 Jan 16. Neurology. 2025. PMID: 39819099 Free PMC article.
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-González L, Madrenas L, Güell I, Clotet B, Izquierdo-Useros N, Raïch-Regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, G Prado J, Pérez-Caballero R, Bernad L, Plana M, Esteban I, Aurrecoechea E, Taleb RA, McSkimming P, Soriano A, Nava J, Anagua JO, Ramos R, Martí Lluch R, Corpes Comes A, Otero Romero S, Martínez-Gómez X, Camacho-Arteaga L, Molto J, Benet S, Bailón L, Arribas JR, Borobia AM, Queiruga Parada J, Navarro-Pérez J, Forner Giner MJ, Lucas RO, Vázquez Jiménez MDM, López Fernández MJ, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, García PM, de la Villa S, Rodríguez Fernández S, Prat T, Torroella È, Ferrer L. Corominas J, et al. Among authors: martinez gomez x. Vaccine. 2025 Feb 15;47:126685. doi: 10.1016/j.vaccine.2024.126685. Epub 2025 Jan 13. Vaccine. 2025. PMID: 39809095 Free article. Clinical Trial.
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F; CombiVacS Study Group. García-Pérez J, et al. iScience. 2024 Aug 14;27(9):110728. doi: 10.1016/j.isci.2024.110728. eCollection 2024 Sep 20. iScience. 2024. PMID: 39286494 Free PMC article.
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.
Carvajal R, Zabalza A, Carbonell-Mirabent P, Martínez-Gómez X, Esperalba J, Pappolla A, Rando A, Cobo-Calvo A, Tur C, Rodriguez M, Río J, Comabella M, Castilló J, Rodrigo-Pendás JÁ, Braga N, Mongay-Ochoa N, Guío-Sánchez C, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Midaglia L, Borras-Bermejo B, Galán I, Sastre-Garriga J, Montalban X, Otero-Romero S, Tintoré M. Carvajal R, et al. Among authors: martinez gomez x. JAMA Netw Open. 2024 Apr 1;7(4):e246345. doi: 10.1001/jamanetworkopen.2024.6345. JAMA Netw Open. 2024. PMID: 38607624 Free PMC article.
Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona.
Fornaguera M, Parés-Badell O, Carbonés-Fargas Í, Andrés C, Rodrigo-Pendás JÁ, Borras-Bermejo B, Armadans-Gil L, Tejada G, Guananga D, Vivet-Escalé M, Peñalver-Piñol A, Torrecilla-Martínez I, Del Oso A, Martínez-Gómez X, Antón A, Otero-Romero S. Fornaguera M, et al. Among authors: martinez gomez x. Vaccines (Basel). 2023 Sep 2;11(9):1450. doi: 10.3390/vaccines11091450. Vaccines (Basel). 2023. PMID: 37766127 Free PMC article.
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
Carvajal R, Tur C, Martínez-Gómez X, Bollo L, Esperalba J, Rodriguez M, Pappolla A, Cobo-Calvo A, Carbonell P, Borras-Bemejo B, Río J, Castilló J, Braga N, Mongay-Ochoa N, Rodrigo-Pendás JÁ, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Galán I, Comabella M, Sastre-Garriga J, Montalban X, Tintoré M, Otero-Romero S. Carvajal R, et al. Among authors: martinez gomez x. Mult Scler. 2023 Dec;29(14):1841-1848. doi: 10.1177/13524585231200303. Epub 2023 Sep 20. Mult Scler. 2023. PMID: 37728389 Free PMC article.
64 results